Pharmaceutical companies are tasked with managing vast volumes of patient data, product information and safety reports. Yet, much of this valuable intelligence remains buried in transcripts, call recordings or unstructured documents. Regulators depend on this information to understand the full story of a drug when identifying potential risks and evaluating the safety and efficacy of treatments.
Modern pharmacovigilance demands more than compliance checklists. Today’s pharmacovigilance
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
The Future of Pharmacovigilance: How Agentic AI and Automation Are Redefining Drug Safety
For decades, drug safety has depended on one simple but demanding task: turning fragments of information from patients, physicians, and trials into clear signals that protect lives. Today, that responsibility sits at the center of a digital revolution. Artificial intelligence and automation are transforming pharmacovigilance from a manual, reactive discipline into one that is fast, predictive, and globally connected. The change is cultural, reshaping how safety professionals think, collaborate,
Read More
A Practical Sleep-Based Framework for Digital Phenotyping in Bipolar Care
Digital phenotyping has held promise in mental healthcare for over a decade, but until recently, few approaches offered both a stable evidence base and a clear path to clinical deployment. That’s starting to change — particularly for bipolar disorder. Recent studies published in Acta Psychiatrica Scandinavica and npj Digital Medicine show that variations in sleep-wake timing, total sleep time, and daily activity regularity can signal near‑term mood instability in bipolar disorder, reflecting
Read More
Converge Bio Lands $25M to Replace Trial-and-Error Drug Discovery
What You Should Know
- Converge Bio has announced a $25M Series A funding round led by Bessemer Venture Partners, bringing its total raised to $30M.
- Moving beyond the "AI promise" gap, the company provides end-to-end AI systems that plug directly into existing drug development workflows, already serving over a dozen pharmaceutical and biotech customers to optimize target discovery and protein manufacturing.
The Systemic Pivot: Bridging the Gap Between Promise and Reality
While
Read More
NVIDIA and Eli Lilly Launch AI Co-Innovation Lab to Reinvent Drug Discovery
What You Should Know
- NVIDIA and Eli Lilly and Company have announced a historic $1B, five-year investment to launch an AI co-innovation lab in the San Francisco Bay Area.
- Utilizing the NVIDIA BioNeMo platform and the next-generation Vera Rubin architecture, the lab will co-locate top AI engineers with biology experts to build a "continuous learning system" that integrates agentic wet labs with robotic manufacturing and physical AI.
The "Continuous Learning" Framework: Connecting
Read More
Eli Lilly Taps Chai Discovery’s Frontier AI to Design ‘Computer-Aided’ Biologics
What You Should Know
- Eli Lilly and Company has entered a strategic collaboration with Chai Discovery to deploy frontier AI for the design of novel biologic therapeutics.
- The partnership includes the development of an exclusive, purpose-built AI model trained on Lilly’s proprietary data, leveraging Chai's Chai-2 platform to compress discovery timelines from months to weeks.
The "Zero-Shot" Revolution: Slashing Discovery Timelines
In the world of biologics, antibody design has
Read More
Amazon Pharmacy Disrupts Weight Loss Market with Oral Wegovy: $149 Cash-Pay Option and Same-Day Delivery
What You Should Know
- Amazon Pharmacy has officially added Novo Nordisk’s Wegovy® pill—the first and only FDA-approved oral GLP-1 for weight management—to its nationwide delivery platform.
- To lower barriers to care, Amazon is offering a transparent cash-pay option starting at $149 per month for those without insurance, while eligible commercially insured customers may pay as little as $25.
The Oral Shift: Removing the Needle Barrier
The "Wegovy pill" represents a massive
Read More
Smarter Media Planning: How Pharma Marketers are Solving the 2026 FDA Compliance Gap
Pharma advertising is entering a period of accelerated change. As the Food and Drug Administration increases oversight of direct‑to‑consumer promotions, marketers are rethinking how they reach patients and consumers. New guidance aimed at improving risk communication and ensuring message accuracy is prompting brands to diversify their media strategies and invest in channels that balance reach, trust, and regulatory responsibility.
Marketers Are Reassessing the Full Advertising Mix
Spending
Read More
Topos Bio Emerges from Stealth to Tackle Disordered Proteins with $10.5M and Frontier AI
What You Should Know
- Topos Bio has emerged from stealth with $10.5M in seed funding to solve one of the most persistent challenges in medicine: targeting intrinsically disordered proteins (IDPs). The seed funding was led by Boldstart, Threshold, and Neo, with participation from notable angel investors including Dara Khosrowshahi (CEO of Uber) and Naveen Rao (CEO of Unconventional AI).
- While traditional models like AlphaFold focus on static structures, Topos Bio’s foundation model,
Read More
Verana Health Acquires COTA to Build Multi-Specialty RWD Powerhouse
What You Should Know:
- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced the merger with COTA Healthcare®.
- The merger expands the company’s therapeutic offerings in data and software solutions for real-world insights that accelerate clinical research, expedite treatment options, and improve patient care. Terms of the transaction were not disclosed.
Building a Multi-Specialty Engine for
Read More
